Adsorption of the cis-[Pt(NH3)2(P2O7)]2 − (phosphaplatin) on hydroxyapatite nanocrystals as a smart way to selectively release activated cis-[Pt(NH3)2Cl2] (cisplatin) in tumor tissues

• Phosphaplatin can work as a cisplatin precursor in the presence of hydroxyapatite.
• Hydroxyapatite could be an important activating agent for drugs.
• Hydroxyapatite could be selectively localized in tumor tissues.

The relevant adsorption of cis-[Pt(NH3)2(P2O7)]2 − (phosphaplatin) on hydroxyapatite nanocrystals (nHAP) was observed and studied in water suspension. Phosphaplatin cytotoxicity, which is very low for HeLa, MCF-7 and HS-5 cell lines could be enhanced, reaching that of cisplatin, by interaction with solid nHAP. This effect stems from nHAP ability to catalyze the phosphaplatin hydrolysis, producing the same hydrolytic species responsible for cisplatin antitumor activity.

Adsorption of cis-[Pt(NH3)2(P2O7)]2 − (phosphaplatin) on hydroxyapatite nanocrystals (nHAP) was observed in water. The generally low cytotoxicity of phosphaplatin, could be enhanced, reaching that of cisplatin, by interaction with nHAP. This effect stems from nHAP ability to catalyze phosphaplatin hydrolysis, giving the hydrolytic species responsible for cisplatin antitumor activity.Figure optionsDownload as PowerPoint slide